Literature DB >> 16118106

Desmopressin is a safe drug for the treatment of enuresis.

Roberto Del Gado1, Donatella Del Gaizo, Marina Cennamo, Roberta Auriemma, Gabriella Del Gado, Mariateresa Vernì.   

Abstract

OBJECTIVE: To verify the safety of desmopressin treatment and its associated side-effects in a large number of patients.
MATERIAL AND METHODS: The study was conducted in accordance with the guidelines of the Italian Club for Nocturnal Enuresis, whose criteria are: age >5 years; absence of malformations and infections of the urinary tract; absence of psychological disorders or neurological alterations; number of "wet nights" >5-7; control of liquid intake during the afternoon and evening; monitoring of serum electrolytes before beginning treatment; control of body weight before the beginning of treatment and during the first 4-5 days of therapy; and the informed consent of the parents. The therapeutic regimen provided for a maximum dose of desmopressin of 40 microg/day (four puffs/nostril or two tablets), starting from an initial dosage of 20 microg/day (two puffs/nostril or one tablet) 1 h before going to bed. The study involved two groups of patients with monosymptomatic enuresis: some of them had been administered desmopressin in the form of a spray and others in the form of tablets.
RESULTS: A small percentage of patients presented mild, transient side-effects; in no case were severe side-effects verified.
CONCLUSION: Desmopressin is a safe drug with a low incidence of side-effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118106     DOI: 10.1080/00365590410018729

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  2 in total

1.  Use of desmopressin and concomitant use of potentially interacting drugs in elderly patients in Sweden.

Authors:  Rickard Ljung
Journal:  Eur J Clin Pharmacol       Date:  2008-01-08       Impact factor: 2.953

2.  Efficacy of desmopressin in treatment of nocturia in elderly men.

Authors:  Bijan Rezakhaniha; Nahid Arianpour; Soheila Siroosbakhat
Journal:  J Res Med Sci       Date:  2011-04       Impact factor: 1.852

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.